8-KMaterial AgreementsFinancial EventsOther Events+1

QUEST DIAGNOSTICS INC 8-K Report, Material Agreement (Feb 5, 2007)

Filed February 5, 2007For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) has filed an 8-K report detailing a material definitive agreement and a new financial obligation. On January 31, 2007, the company entered into a $450 million senior unsecured interim credit facility with Bank of America, N.A. The primary purpose of this facility is to fund the acquisition of HemoCue and related expenses. The facility matures on January 31, 2008, and carries an interest rate tied to published rates plus an applicable margin that adjusts based on Quest Diagnostics' public debt rating, with options for LIBOR-based interest rate contracts. This new credit facility, along with the concurrent acquisition of HemoCue, represents a significant strategic move for Quest Diagnostics. Investors should note that the credit agreement includes covenants similar to existing facilities, which may impact the company's future ability to incur additional debt. Furthermore, mandatory pre-payment is required in the event of future debt or equity issuances by the company, subject to specific exceptions. The acquisition itself was publicly announced on February 1, 2007.

Key Highlights

  • 1Quest Diagnostics secured a $450 million senior unsecured interim credit facility due January 31, 2008.
  • 2The primary use of funds is to acquire HemoCue and cover related acquisition costs.
  • 3The credit facility is guaranteed by the company's wholly owned domestic subsidiaries.
  • 4Interest rates are variable, based on published rates plus a margin determined by Quest Diagnostics' debt rating, with LIBOR options available.
  • 5The agreement includes covenants that maintain existing financial ratio requirements and may restrict future indebtedness.
  • 6Mandatory pre-payment of the loan is triggered by future debt or equity issuances, with limited exceptions.
  • 7The acquisition of HemoCue was announced on February 1, 2007.

Frequently Asked Questions

The $450 million senior unsecured interim credit facility is primarily intended to finance the acquisition of HemoCue and to pay associated fees, costs, and expenses related to this acquisition.

The interim credit facility matures on January 31, 2008.

The credit facility contains covenants that are consistent with Quest Diagnostics' existing senior unsecured revolving credit facility. These typically include requirements to maintain certain financial ratios, which could limit the company's ability to take on additional debt or pursue certain other financial actions.

Yes, the interim credit facility includes a provision for mandatory pre-payment of the outstanding loan amount if Quest Diagnostics issues new debt or equity, subject to certain limited exceptions outlined in the agreement.